Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
01 nov. 2023 17h00 HE
|
Phathom Pharmaceuticals
FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 yearsVOQUEZNA® met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3...
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
26 sept. 2023 08h01 HE
|
Phathom Pharmaceuticals
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile...
4.9% CAGR for Gastrointestinal Drugs Market Size Worth $71.3Bn, Globally, by 2027 with Irritable Bowel Syndrome Segment Driving Growth During 2020-2027 | Report by The Insight Partners
11 juil. 2023 10h55 HE
|
The Insight Partners
Pune, India, July 11, 2023 (GLOBE NEWSWIRE) -- The Insight Partners latest study on "Gastrointestinal Drugs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug...
Global Pediatric Gastroenterology Market Size & Trends
23 juin 2023 10h59 HE
|
Global Market Estimates
Brooklyn, New York, June 23, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Pediatric Gastroenterology Market is projected to...
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
12 juin 2023 08h01 HE
|
Phathom Pharmaceuticals
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
01 juin 2023 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
23 mai 2023 16h00 HE
|
Phathom Pharmaceuticals
Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year endIf approved, vonoprazan would be the first innovative acid...
Phathom Pharmaceuticals Reports First Quarter 2023 Results
10 mai 2023 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
09 mai 2023 08h00 HE
|
Phathom Pharmaceuticals
Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristicsMeta-analysis...
Global Gastrointestinal Diagnostics Market to 2030: Increasing Prevalence of Gastrointestinal Disorders Drives Growth
04 avr. 2023 11h04 HE
|
Research and Markets
Dublin, April 04, 2023 (GLOBE NEWSWIRE) -- The "Gastrointestinal Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Endoscopy, Blood Test), by Technology, by Application, by...